Brokerages Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target at $68.20

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given an average recommendation of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $68.20.

A number of analysts recently weighed in on the stock. Barrington Research increased their price target on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 28th. StockNews.com upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, March 23rd. Finally, KeyCorp initiated coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They issued a “sector weight” rating on the stock.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director Lawrence J. Jasinski sold 5,110 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the transaction, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other LeMaitre Vascular news, Director John A. Roush sold 7,500 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $69.00, for a total transaction of $517,500.00. Following the transaction, the director now owns 2,278 shares of the company’s stock, valued at approximately $157,182. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Lawrence J. Jasinski sold 5,110 shares of LeMaitre Vascular stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the sale, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 114,036 shares of company stock valued at $7,873,749. 12.50% of the stock is owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Comerica Bank purchased a new stake in LeMaitre Vascular in the second quarter valued at approximately $114,400,000. Mesirow Institutional Investment Management Inc. purchased a new stake in shares of LeMaitre Vascular during the 4th quarter valued at $8,837,000. Congress Asset Management Co. MA increased its holdings in shares of LeMaitre Vascular by 36.3% during the 3rd quarter. Congress Asset Management Co. MA now owns 508,379 shares of the medical instruments supplier’s stock worth $27,696,000 after buying an additional 135,266 shares during the last quarter. Vanguard Group Inc. raised its position in shares of LeMaitre Vascular by 10.1% in the 1st quarter. Vanguard Group Inc. now owns 1,426,235 shares of the medical instruments supplier’s stock worth $66,278,000 after buying an additional 130,881 shares during the period. Finally, Ranger Investment Management L.P. boosted its holdings in LeMaitre Vascular by 15.8% in the third quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock valued at $48,968,000 after acquiring an additional 122,601 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $67.20 on Friday. The company has a fifty day moving average of $63.00 and a two-hundred day moving average of $56.82. The company has a market capitalization of $1.50 billion, a PE ratio of 50.15, a P/E/G ratio of 2.82 and a beta of 0.88. LeMaitre Vascular has a 1 year low of $44.27 and a 1 year high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.02. The firm had revenue of $48.90 million during the quarter, compared to analysts’ expectations of $49.01 million. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The business’s revenue was up 19.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.25 EPS. On average, research analysts expect that LeMaitre Vascular will post 1.66 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Thursday, March 14th will be issued a dividend of $0.16 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.14. This represents a $0.64 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend is Wednesday, March 13th. LeMaitre Vascular’s dividend payout ratio is currently 47.76%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.